AbbVie announced results from a Phase 2 study of venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML).
The Phase 2 open-label, multicenter, clinical trial was designed to evaluate the preliminary efficacy of venetoclax in 32 patients with relapsed/refractory AML or as frontline therapy for patients who are unfit for intensive therapy. Results demonstrated that in the venetoclax group, an overall response rate (ORR) of 19% was observed, with two patients achieving a complete response and four patients achieving a complete response with incomplete blood count recovery.
Venetoclax is an investigational inhibitor of the B-cell lymphoma-2 (BCL-2) protein, which prevents apoptosis of some cells, including lymphocytes. BCL-2 can be highly expressed in cancers in the lymph nodes, spleen, and other organs of the immune system.
For more information call (800) 633-9110 or visit AbbVie.com.